Trial
NCT00574275
Aflibercept Compared to Placebo in Term of Efficacy in Patients Treated With Gemcitabine for Metastatic Pancreatic Cancer
Phase IIITERMINATEDSAFETYConfidence: MEDIUM
Sponsor
Sanofi
Collaborators
Regeneron Pharmaceuticals
Condition
Pancreatic Neoplasm
Intervention
Aflibercept (ziv-aflibercept, AVE0005, VEGF trap, ZALTRAP®)
Why stopped
Data Monitoring Committee concluded after a planned interim analysis that aflibercept added to gemcitabine would be unable to demonstrate improved survival
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2016-06-07